In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MGI Pharma gets exclusive rights to SuperGen's Dacogen

Executive Summary

The same day it reported it was expanding its cancer franchise by buying Zycos for $50mm and Aesgen for $32mm, MGI Pharma also announced a licensing deal with SuperGen. MGI now has exclusive worldwide development, marketing, and distribution rights to Dacogen (decitabine), a methylase inhibitor for patients with myelodysplastic syndromes (MDS, cancer of the bone marrow).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies